ScholarWorks@SUNGKYUNKWAN UNIVERSITY: PARK, HEE CHUL

Detailed Information

PARK, HEE CHUL (박희철)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Radiotherapy:36||Hepatocellular carcinoma:31||radiotherapy:23||hepatocellular carcinoma:20||Rectal neoplasms:10||Radiation therapy:10||Rectal cancer:9||Proton beam therapy:7||proton beam therapy:6||Carcinoma:6||Toxicity:6||radiation therapy:5||rectal cancer:5||Chemoradiotherapy:5||Stereotactic body radiotherapy:4||Hepatocellular:4||prognosis:4||chemoradiation:4||Liver:4||Preoperative chemoradiotherapy:4||Recurrence:4||toxicity:4||Colorectal cancer:3||Guidelines:3||chemoradiotherapy:3||Neoadjuvant chemoradiotherapy:3||Proton:3||Magnetic resonance imaging:3||Management:3||Survival:3||Radiation effects:3||proton therapy:3||rectal neoplasm:3||recurrence:3||Treatment planning:3||response:3||intensitymodulated radiotherapy:3||survival:3||liver cancer:3||Response:3||Portal vein tumor thrombosis:3||Spinal metastases:2||Neoplasm metastasis:2||Total mesorectal excision:2||complication:2||Sorafenib:2||Metastasis:2||radiosensitization:2||Immunotherapy:2||Transarterial chemoembolization:2||hepatocellular:2||overall survival:2||hyperthermia:2||Neoadjuvant therapy:2||Local excision:2||magnetic resonance imaging:2||Transcatheter arterial chemoembolization:2||Mucosa associated lymphoid tissue lymphoma:2||Dose fractionations:2||Risk factors:2||inflammation:2||s practice patterns:2||Abscopal effect:2||oncologic outcome:2||ChildPugh score:2||spine:2||Tumor burden:2||Reirradiation:2||nivolumab:2||stereotactic body radiotherapy:2||Tumor regression grade:2||metaanalysis:2||metastasis:2||Hyperthermia:2||HCC:2||Rectal volume:2||tissue expander:2||Secondary cancer risk:2||Complete remission:2||Prognosis:2||Leukopenia:2||TACE:2||Biomarkers:2||Carcinoembryonic antigen:2||Chemoradiation:2||Stomach:2||prognostic factor:2||Thermometry:2||Chemoembolization:2||Validation:2||Mcl1:1||Mesoporous silica nanoparticles:1||Metal stent:1||Metformin:1||MnTnHex2PyP:1||Monte Carlo:1||Monte Carlo dose calculation:1||Monte Carlo simulation:1||Multidisciplinary approach:1||Murine model:1||NOD2:1||Nanoparticles:1||Nasopharyngeal Neoplasms:1||Neoadjuvant:1||Neoadjvant therapy:1||Nivolumab:1||Nonsmall cell lung cancer:1||Normal tissue complication probability:1||Olaparib:1||Organs at risk:1||PD1:1||PDL1:1||Pain:1||Palliation:1||Pancreatic cancer:1||Particle accelerator:1||Passive scattering:1||Pathologic complete response:1||Pathology:1||Patientreported outcomes:1||Pembrolizumab:1||Pencilbeam scanning:1||Photon:1||Physician&apos:1||Practice guidelines:1||Predictive factor:1||Preoperative anemia:1||Prognostic index:1||Prophylactic:1||Prospective phase II study:1||Prostate canc:1||Prostatic neoplasms:1||Proton therapy:1||Quality Assurance:1||Quality assurance:1||Quality of life:1||RTOG 0631 protocol:1||RTOG 0631 프로토콜:1||Radiation oncology:1||Radiation recall dermatitis:1||Radiation the:1||Radiationtherapy:1||Radiofrequency ablation:1||Radiosurgery:1||Radiotherapy Planning ComputerAssisted:1||Rectal neoplasm:1||Respiration gated radiation therapy:1||Respiration regularity:1||Respiration signal analysis program:1||Respiration training:1||Respiratory gating:1||Response Evaluation Criteria in Solid Tumors (RECIST):1||Restaging:1||Retroperitoneal sarcoma:1||SOD mimic:1||Salvage therapy:1||Sarcopenia:1||Selective internal radiation therapy:1||Simultaneously integrated boost:1||Simvastatin:1||Skeletalrelated event:1||Spinal cord compression:1||Spinal neoplasms:1||Spine:1||Spine radiosurgery:1||Stomach neoplasms:1||Surgery:1||Surgery alone:1||Surgery interval:1||Survey:1||T3N0:1||TPS QA:1||Tablet PC:1||Therapeutic:1||Threedimensional conformal radiotherapy:1||Thrombosis:1||Trans:1||Treatment response:1||TrueBeam:1||Tumor:1||Tumor hypoxia:1||Tumor microenvironment:1||Tumor response:1||Tumor spheroids:1||Twoweek course:1||Tyrosine kinase inhibitor:1||VMAT:1||Xray therapy:1||activating transcription factor 4 (ATF4):1||adjuvant therapy:1||anastomotic leakage:1||biliary complication:1||biliary tract neoplasm:1||biodegradation:1||bleeding:1||bodycentred cubic:1||bone metastasis:1||capecitabine:1||carbon ion radiotherapy:1||carcinoma:1||cervical cancer:1||chronic liver disease:1||cluster morphology:1||combination therapy:1||combined modality therapy:1||concurrent chemoradiotherapy:1||cone beam CT:1||conformal radiotherapy:1||contrast agent:1||correlation:1||crypt regeneration:1||crypt survival:1||data collection:1||diffusionweighted imaging:1||dose distortion:1||dose enhancement:1||dose enhancement ratio:1||dose escalation:1||dosevolume histogram:1||efficacy:1||epithelial regeneration:1||external beam radiation therapy:1||gadoxetate disodiumenhanced MRI:1||gastroduodenal toxicity:1||gastrointestinal tract:1||genetic diagnosis:1||gold nanoparticle:1||great vessel invasion:1||head and neck cancer:1||hepatocel:1||hypofractionated treatment:1||immunohistochemistry:1||immunotherapy:1||internal/external fiducials:1||intestinal stem cells:1||intrahepatic recurrence:1||lateral pelvic lymph node:1||leaf width:1||lenvatinib:1||local control:1||locoregional r:1||lung cancer:1||lymph node dissection:1||lymph node metastasis:1||lymphocyte:1||lymphocyte‐to‐monocyte ratio:1||manganese porphyrin:1||marker tracking:1||mass spectrometry:1||monocyte:1||mouse model:1||multileaf collimator:1||nanoparticle:1||nanoparticles:1||neoadjuvant CCRT:1||neoadjuvant treatment:1||neoplasm:1||neutrophil:1||neutrophil‐to‐lymphocyte ratio:1||nomogram:1||nonsmall cell lung cancer:1||nonsmall cell lung carcinoma:1||organoid:1||p53:1||pancreatic adenocarc:1||pancreatic cancer:1||pancreaticobiliary tract cancer:1||panobinostat:1||particle beam radiotherapy:1||patient care:1||patient external surface:1||patient motion monitoring:1||patient safety:1||perihilar region:1||phlorotannins:1||physician&apos:1||platelet:1||platelet‐to‐lymphocyte ratio:1||polymer:1||portal vein tumour thrombosis:1||postoperative chemotherapy:1||predictive biomarker:1||preoperative chemor:1||preoperative chemoradiotherapy:1||proteomics:1||pulmonary metastasis:1||radiation:1||radiation dermatitis:1||radiation pneumonitis:1||radiosensitivity:1||radiotherapy dosage:1||ratio:1||rea:1||reactive oxygen species:1||registry:1||relative biological effectiveness:1||respiratory gating:1||retroperitoneal sarcoma:1||safety:1||sarcopenia:1||sorafenib:1||stage IV:1||staging system:1||stereotactic ablative body radiotherapy:1||supraclavicular lymph node metastasis:1||survivin:1||systemic inflammatory marker:1||threedimensional confor:1||threedimensional conformal radiotherapy:1||total mesorectal excision:1||transcatheter arterial chemoembolization:1||trend:1||tumor hypoxia:1||tumor microenvironment:1||tumor regression:1||unfolded protein response (UPR):1||vertebral compression fracture:1||virtual simulator:1||동시통합추가치료법:1||척추뼈전이암:1||#8722:1||체부정위적방사선치료계획:1||(&:1||)agelamide D:1||.:1||4 dimensional radiation therapy:1||Adjuvant radiotherapy:1||Aged:1||Alternative:1||Anus neoplasms:1||Apparent diffusion coefficient:1||Appointments and schedules:1||Arterioportal shunt:1||Asymptomatic brain metastases in NSCLC:1||BaSO4:1||Barcelona Clinic Liver Cancer stage C:1||Biliary tract neoplasm:1||Bone metastasis:1||CD8:1||CXCL13:1||Capecitabine:1||Carcinoma, hepatocellular:1||Chemotherapy:1||ChildPugh B:1||Clinical practice pattern:1||Colon cancer:1||Colorectal:1||Colorectal neoplasms:1||Combination index:1||Complication:1||Computer assisted image analysis:1||Computerassisted diagnosis:1||Computerassisted radiotherapy planning:1||Concurrent chemoradiation therapy:1||Consensus:1||Data collection:1||Diabetes:1||Diagnosis:1||Diseasefree survival:1||Dose calculation parameters:1||Dose fractionation:1||Dose volume histogram:1||Equivalence:1||Esophageal cancer:1||Esophagorespiratory fistula:1||External beam radiotherapy:1||FOXP3:1||Fe3O4/TaOx:1||Fracture:1||Fractures, compression:1||Fucoidan:1||GATE:1||Gadolinium DTPA:1||Gastroduod:1||Gastroduodenal toxicity:1||Genetic mutations:1||HD120:1||Healthrelated quality of life:1||Helical tomotherapy:1||Hepatectomy:1||Hepatic toxicity:1||Hepatitis B virus:1||Hepatocellular carcinoma, nonresectable:1||Highthroughput screening platform:1||Hypofractionated radiotherapy:1||IGRT:1||IMRT:1||Imageguided rad:1||Immune checkpoint inhibitors:1||Induced hyperthermia:1||Inflammation:1||Inguinal:1||IntensityModulated:1||Intensitymodulated radiotherapy:1||Internal/external fiducials:1||Intrahepatic cholangiocarcinoma:1||Keywords: Proton therapy:1||Korea:1||Lateral lymph node:1||Lateral pelvic recurrence:1||Liver metastases:1||Liver neoplasms:1||Local:1||Local control:1||Local modality:1||Lung cancer:1||Lymph nodes:1||MR imaging:1||MRI:1||Margins of excision:1||Marker tracking:1||

STATISTICS: Total View :5,308,086; Today View :3,454

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE